ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease.Despite being treated with standard-of-care renal drug therapy (ACEi, SGLT2, statin, and ezetimibe), the patient authorized by FDA to receive VAR 200 is showing continued kidney disease progression. Because her kidney biopsy demonstrated lipid deposition, the tre ...